Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Sickle Cell Gene Therapy for Young Kids

2.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

3.

Combo Therapy Boosts Early CML Response but Not Long Term

4.

Increased Exercise May Lower the Risk of Prostate Cancer.

5.

Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot